NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...
First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...
According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...
Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...
The news for the chocolate industry is a welcome development, as businesses and scientists grapple with crop shortages.
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...
Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is conducting a Phase 3 ...
CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...
Researchers from the UK and Germany have announced to have developed pigs that are resistant to Classical Swine Fever.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback